Supreme Court Report

Supreme Court of the United States · Official docket →

PharMerica Corporation v. United States, ex rel. Marc Silver

Paid petition · United States Court of Appeals for the Third Circuit, No. 16-4418 · judgment September 4, 2018


Certiorari denied · October 7, 2019
Pre-decision estimate: 5% cert probability

Before the decision, roughly the 4.1% base rate. The model weighted this up for a Third Circuit decision below, a circuit split argued in the petition, and a business petitioner.

Question presented

The Public Disclosure Bar (the “Bar”) of the False Claims Act (“FCA”), 31 U.S.C. § 3730(e)(4), provides that courts must dismiss an FCA case brought as a qui tam action by a relator who is not an original source of the information in his complaint “if substantially the same allegations or transactions as alleged in the action were publicly disclosed” in certain enumerated sources.1 The Bar functions as a gatekeeping device to prevent parasitic lawsuits based on previously disclosed information, while allowing true insiders to advance new claims. The Circuits have been unable to devise a uniform standard for ascertaining when the Bar applies, and in doing so have deviated from the plain language of the Bar, resulting in conflict and confusion among the Circuits. The questions presented are: 1. Whether a relator’s admission that he, in fact, derived his complaint from public disclosures triggers the Bar, requiring an analysis of whether such a relator is an original source of the information in his complaint, as every other Circuit to consider the issue has held 1 Prior to its amendment in 2010, the Bar provided that “[n]o court shall have jurisdiction over an action under this section based upon the public disclosure of allegations or transactions” in certain enumerated sources “unless the person bringing the action is an original source of the information.” 31 U.S.C. § 3730(e)(4) (2006).

Counsel of record

For petitioner
Michael Robert Manthei
Holland & Knight LLP

For respondent
Sherrie R. Savett
Berger & Montague

Case

Conference history
Distributed for 2 conferences

Proceedings

  1. Oct 07 2019
    Motion for leave to file amici brief filed by Pharmaceutical Research and Manufacturers of America, et al. GRANTED.
  2. Oct 07 2019
    Petition DENIED.
  3. Jun 19 2019
    DISTRIBUTED for Conference of 10/1/2019.
  4. Jun 17 2019
    Reply of petitioner PharMerica Corporation filed. (Distributed)
  5. Jun 03 2019
    Brief of respondent United States, ex rel. Marc Silver in opposition filed.
  6. May 03 2019
    Motion to extend the time to file a response is granted and the time is extended to and including June 3, 2019.
  7. May 01 2019
    Motion to extend the time to file a response from May 3, 2019 to June 3, 2019, submitted to The Clerk.
  8. Apr 03 2019
    Response Requested. (Due May 3, 2019)
  9. Mar 27 2019
    DISTRIBUTED for Conference of 4/12/2019.
  10. Mar 11 2019
    Motion for leave to file amici brief filed by Pharmaceutical Research and Manufacturers of America, et al.
  11. Mar 04 2019
    Blanket Consent filed by Petitioner, PharMerica Corporation
  12. Feb 06 2019
    Petition for a writ of certiorari filed. (Response due March 11, 2019)